RAMONA
Regimen
- Experimental
- nivolumab + ipilimumab (after nivolumab run-in)
Population
Elderly (>=65 years) ESCC patients with disease progression or recurrence after first-line therapy
Key finding
mOS 7.2 mo (95% CI 5.7-12.4) in elderly ESCC 2L with nivo+ipi, historically better than chemo
Source: PMID 36098320